X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants

Content Team by Content Team
7th February 2022
in News
T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced that its T2SARS-CoV-2™ Panel detects Omicron COVID-19 subvariants BA.1, BA.2, and BA.3.

According to the Centers for Disease Control and Prevention, the Omicron variant of the SARS-CoV-2 virus now accounts for 99.9% of all COVID-19 infections currently circulating in the United States.1 Although still considered an Omicron variant, there has recently been a worldwide increase in the Omicron subvariant BA.2. Since the Company’s November 30, 2021 announcement that the T2SARS-CoV-2 Panel detects the Omicron variant based on in silico analysis, T2 Biosystems has continued to monitor the ability of the T2SARS-CoV-2 Panel to detect all reported Omicron subvariants.

To confirm that the T2SARS-CoV-2 Panel would detect the new Omicron subvariants (BA.1, BA.2, and BA.3), T2 Biosystems performed in silico analysis using genetic sequences in the GISAID database. Based on the sequences that were available on February 1, 2022, over 5,000 BA.1, 2368 BA.2, and 266 BA.3 sequences were evaluated. This in silico analysis demonstrated that the T2SARS-CoV-2 Panel would be able to detect all Omicron subvariants.

“We are proud to announce that the T2SARS-CoV-2 Panel is capable of detecting all Omicron subvariants, enabling healthcare providers to make accurate decisions about their patients’ health,” said John Sperzel, Chairman and CEO at T2 Biosystems. “Despite the broad use of at-home COVID-19 antigen tests, hospitals continue to rely on molecular or PCR tests, including the T2SARS-CoV-2 Panel, to identify acute COVID-19 infections. As such, we are seeing high demand by U.S. hospitals for our T2SARS-CoV-2 Panel.”

The T2SARS-CoV-2 Panel, which has demonstrated a clinical sensitivity of 95 percent and a specificity of 100 percent, provides results in under two hours utilizing an upper respiratory swab sample. The test runs on the Company’s fully-automated T2Dx® Instrument, which is capable of performing seven tests simultaneously and up to sixty tests per day.

The T2Dx Instrument is also capable of running the FDA-cleared T2Bacteria® Panel and T2Candida® Panel, the only FDA-cleared assays able to detect sepsis-causing pathogens directly from whole blood in three to five hours, without the need to wait days for blood culture results. By providing timely results, the panels enable clinicians to target therapy faster for their patients suspected of sepsis, often before the second dose of antimicrobials are administered, leading to better patient outcomes, improved antimicrobial stewardship, and reductions in length of stay in the hospital.

The T2Bacteria® and T2Candida® Panels remain especially relevant during the pandemic, as data suggests that the COVID-19 virus is highly correlated with bacterial and fungal co-infections that may lead to sepsis, and death.

Previous Post

Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

Next Post

America Facing Heart Health Issues Since The Pandemic Began

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
America Facing Heart Health Issues Since The Pandemic Began

America Facing Heart Health Issues Since The Pandemic Began

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In